vpb

Aplodan (creatinol-O-phosphate) exhibits antiischemic and antiarrhythmic capacity and protective action on the cell membrane. Aplodan can be used in research on the ischemic heart or ischemic heart disease with persistent ventricular premature beats.

BGT226 (NVP-BGT226) is a novel dual PI3K/mTOR inhibitor, targeting PI3K α, β, and γ with IC50 values of 4 nM, 63 nM, and 38 nM, respectively.

NVP-BSK805 2HCl (1092499-93-8(free base)) (BSK 805)(IC50=0.5 nM), a specific and effective ATP-competitive JAK2 inhibitor, is more than 20-fold specificity over JAK1, JAK3 and TYK2.

NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.

Dactolisib Tosylate (BEZ235 Tosylate) is a dual kinase inhibitor targeting PI3K and mTOR, with IC50 values of 4, 75, 7, and 5 nM for PI3Kα, β, γ, and δ, respectively. It also inhibits mTORC1 and mTORC2.

Infigratinib phosphate (BGJ-398 phosphate) is an effective inhibitor of the FGFR family (IC50: 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively).

Buparlisib Hydrochloride (BKM120 HCl) is a specific and orally bioavailable pan-class I PI3K inhibitor that competitively inhibits PI3K/AKT kinase at the nanomolar level and suppresses cancer cell growth, making it suitable for studying breast cancer, glioblastoma, and solid tumours.

Buparlisib (BKM120) is an orally bioavailable specific oral inhibitor of the pan-class I PI3K (IC50s: 52/166/116/nM for p110α, p110β, and p110δ).

NVP-BHG712 isomer shows conserved non-bonded binding to EPHA2 and EPHB4.

Infigratinib (NVP-BGJ398) (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.

Dactolisib (BEZ235) hydrochloride is an orally active dual inhibitor of pan-class I PI3K and mTOR, targeting p110α/γ/δ/β and mTOR, with IC50 values of 4 nM, 5 nM, 7 nM, 75 nM, and 20.7 nM, respectively. It inhibits both mTORC1 and mTORC2.

VER-82576 (NVP-BEP800), a synthetic HSP90β inhibitor (IC50: 58 nM), exhibits >70-fold selectivity against Hsp90 family members Trap-1 and Grp94.

NVP-BQS481 (Compound 1) is a selective inhibitor of spindle motor protein 5 (Eg5), with an IC50 of less than 0.5 nM. It demonstrates significant anti-mitotic and anti-tumor activities, exhibiting an IC50 of 0.09 nM against SK-OV-3ip cells. NVP-BQS481 is suitable for use as a cytotoxic payload in the synthesis of antibody-drug conjugates (ADCs).

Dactolisib (BEZ235) is an orally bioavailable inhibitor of PI3K and mTOR, with IC50 values of 4 nM for p110α, 5 nM for p110γ, 7 nM for p110δ, 75 nM for p110β, and 20.7 nM for mTOR.

NVP-BAW2881 (BAW2881) is a potent and selective VEGFR (vascular endothelial growth factor receptor tyrosine kinase) inhibitor with efficacy in inhibiting chronic and acute skin inflammation.

NVP-BSK805 trihydrochloride is a potent ATP-competitive inhibitor of JAK2, exhibiting IC50 values of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM against JAK2 JH1, JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

BQR-695 (NVP-BQR695) is a phosphatidylinositol 4-kinase (PI4K) inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.

NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.

BGT226 maleate (NVP-BGT226) is a class I PI3K/mTOR inhibitor for PI3Kα/β/γ (IC50: 4/63/38 nM) .

NVP-BBD130 is a stable, ATP-competitive, potent, orally active inhibitor of PI3K and mTOR.

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.

FFA3-Antagonist-6 is a PAM-antagonist of the function of C3 at FFA3.

NVP-BHS345 is a dual inhibitor of TORC1 and TORC2.

Ofloxacin HCl is a synthetic fluoroquinolone ( FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.